Connecting Research for Progress
The Pancreatic Cancer Progress Review Group (PRG) considered progress and identified issues, barriers, and needs across the continuum of pancreatic cancer research. The group delineated and prioritized recommendations for research directions, related scientific questions, and resource and infrastructure needs. The Pancreatic Cancer PRG report is divided into three sections.
This section addressed current research and funding levels for pancreatic cancer and critical issues such as manpower development and training needs, and resource deployment and organization.
The Pancreatic Cancer PRG delineated the following four research priorities: Tumor Biology, Risk/Prevention/Screening/Diagnosis, Therapy, and Health Services Research.
This section delineates resources that are urgently needed to accelerate achievement of the research priorities. Often these recommendations support research priorities in Section 2.
The Pancreatic Cancer PRG offered areas of recommendations. Projects in the Pancreatic Cancer Research Map portfolio are coded to the recommendations that they address.
TB1 - Understand the normal biology
TB2 - Elucidate the development of adenocarcinoma
TB3 - Study natural history of stroma and desmoplasia
TB4 - Host-tumor interactions and therapeutic strategies
TB5 - Specimen banks (tissue)
TB6 - Experimental model systems (no change)
RP1 - Identify factors that contribute to disease development
RP2 - Develop approaches to prevention in high-risk cohorts
RP3 - Develop early detection methods
RP4 - New and expanded registries
RP5 - Specimen banks (biomaterials)
RP6 - Consortia of large, aging cohorts
RP7 - Education for providers and investigators
RP8 - Web-based imaging library
RP9 - Technology centers for gene and protein expression
RP10 - Animal models
TX1 - Discovery and development of targeted therapeutics
TX2 - Development of clinical techniques to assess targeted therapeutics
TX3 - Research for supportive care of patients
TX4 - Facilitate investigator access to targeted therapeutic agents
TX5 - Infrastructure for molecular target assessment (no change)
TX6 - Infrastructure for multidisciplinary clinical trials
HS1 - Identify effective forms of provider/patient communication
HS2 - Study message effectiveness in patient decision making
HS3 - Study requirements and costs of multidisciplinary clinical trials
HS4 - Evaluate current practices in diagnosis and care
HS5 - Survivorship registry
HS6 - Web-based repository to track clinical trial cost
HS7 - Models to apply and validate in community and research settings
HS8 - Education, training, and communication tools
ST1 - Specimen resource (normal and cancerous samples)
ST2 - Database of biological profiles of normal and neoplastic cells
ST3 - New biological sampling techniques
ST4 - Capture knowledge of relevant molecular pathways
ST5 - Gene-based model systems
ST6 - Imaging systems
